Aptamers: an emerging class of therapeutics.

By S. M. Nimjee, C. Rusconi, B. Sullenger. Annual Review of Medicine, 2005

902 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/ab2dfe614b0efb591d2e5a15d447b57ca679f595

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

Citations in the corpus

Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. (2007, methodology): “These ligands are created using a process of systematic evolution of ligands by exponential enrichment (SELEX) (51, 52).”
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras (2006, background): “The smaller size of aptamers compared with that of antibodies ( in vivo delivery by promoting better tissue penetratio”
The delivery of therapeutic oligonucleotides (2016, methodology): “Using the well-known SELEX technique, aptamers can be selected to bind to virtually any receptor with nanomolar to picomolar affinities (274).”
Microfluidics Integrated Biosensors: A Leading Technology towards Lab-on-a-Chip and Sensing Applications (2015, background): “Aptamers are defined as amino acid polymers or a single-stranded nucleic acid that have a high selectivity, specificity and affinity towards a target analyte ranging from small molecules to whole cells [26,28].”
SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. (2007, background): “A ptamers display low to no immunogenicity, which is important for animal or human therapeutic applications (Nimjee et al., 2005b).”
Interfering with disease: a progress report on siRNA-based therapeutics (2007, background): “It should be possible to design siRNA-aptamer chimeras with longer strands (45-55 bases) that are within the range of technical and commercial feasibility for synthesis, but longer molecules may prove difficult to synthesize on a commercial scale.”
Discovery and Development of the G-rich Oligonucleotide AS1411 as a Novel Treatment for Cancer (2009, background): “These include double-stranded DNA oligonucleotides that act as “decoys” for specific transcription factors [5] and aptamer oligonucleotides, which bind to small molecule or proteins by shape-specific recognition [6-8].”